Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

Open access
Braun, David A., Moranzoni, Giorgia, Chea, Vipheaviny, McGregor, Bradley A., Blass, Eryn, Tu, Chloe R., Vanasse, Allison P., Forman, Cleo, Forman, Juliet, Afeyan, Alexander B., Schindler, Nicholas R., Liu, Yiwen, Li, Shuqiang, Southard, Jackson, Chang, Steven L., Hirsch, Michelle S., LeBoeuf, Nicole R., Olive, Oriol, Mehndiratta, Ambica, Greenslade, Haley, Shetty, Keerthi, Klaeger, Susan, Sarkizova, Siranush, Pedersen, Christina B., Mossanen, Matthew, Carulli, Isabel, Tarren, Anna, Duke-Cohan, Joseph, Howard, Alexis A., Iorgulescu, J. Bryan, Shim, Bohoon, Simon, Jeremy M., Signoretti, Sabina, Aster, Jon C., Elagina, Liudmila, Carr, Steven A., Leshchiner, Ignaty, Getz, Gad, Gabriel, Stacey, Hacohen, Nir, Olsen, Lars R., Oliveira, Giacomo, Neuberg, Donna S., Livak, Kenneth J., Shukla, Sachet A., Fritsch, Edward F., Wu, Catherine J., Keskin, Derin B., Ott, Patrick A., Choueiri, Toni K. · 2025 · Nature

Abstract

Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1–6. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient’s tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No dose-limiting toxicities were observed. All patients generated T cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA. Following vaccination, there was a durable expansion of peripheral T cell clones. Moreover, T cell reactivity against autologous tumours was detected in seven out of nine patients. Our results demonstrate that neoantigen-targeting PCVs in high-risk RCC are highly immunogenic, capable of targeting key driver mutations and can induce antitumour immunity. These observations, in conjunction with the absence of recurrence in all nine vaccinated patients, highlights the promise of PCVs as effective adjuvant therapy in RCC. A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-08507-5

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 61

  1. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019). · DOI · Paper page
  2. Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021). · DOI · Paper page
  3. Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S. & Wu, C. J. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 1, 11–15 (2013). · DOI · Paper page
  4. Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020). · DOI · Paper page
  5. Kashima, S. & Braun, D. A. The changing landscape of immunotherapy for advanced renal cancer. Urol. Clin. North Am. 50, 335–349 (2023). · DOI
  6. Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683–694 (2021). · DOI · Paper page
  7. Motzer, R. J. et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401, 821–832 (2023). · DOI · Paper page
  8. Pal, S. K. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400, 1103–1116 (2022). · DOI · Paper page
  9. Allaf, M. et al. LBA67 phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann. Oncol. 33, S1432–S1433 (2022). · DOI
  10. Jocham, D. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363, 594–599 (2004). · DOI · Paper page
  11. Rini, B. I. et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1599–1611 (2016). · DOI · Paper page
  12. Hongo, F. et al. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. Int. J. Urol. 30, 176–180 (2023). · DOI
  13. Achtar, M. S. et al. Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. J. Clin. Oncol. 22, 2589 (2004). · doi:10.1200/jco.2004.22.90140.2589
  14. Rahma, O. E. et al. A pilot clinical trial testing mutant von Hippel–Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J. Transl. Med. 8, 8 (2010). · DOI
  15. Powles, T. et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 1133–1144 (2022). · DOI · Paper page
  16. Liard, C. et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J. Invest. Dermatol. 132, 615–625 (2012). · DOI
  17. Shklovskaya, E., Roediger, B. & Fazekas de St Groth, B. Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J. Immunol. 181, 418–430 (2008). · DOI
  18. Steinman, R. M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1–22 (2012). · DOI · Paper page
  19. Longhi, M. P. et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589–1602 (2009). · DOI · Paper page
  20. Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119–125 (2021). · DOI · Paper page
  21. Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770–2788 (2022). · DOI · Paper page
  22. Bedke, J. et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J. Urol. 32, 31–38 (2014). · DOI
  23. Kubler, H. & Vieweg, J. Vaccines in renal cell carcinoma. Semin. Oncol. 33, 614–624 (2006). · DOI
  24. Kommu, S. Renal-cell carcinoma: vaccination and risk of tumour progression. Lancet 363, 1557 (2004). · doi:10.1016/s0140-6736(04)16169-2
  25. Braiteh, F. et al. Abstract CT169: a phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors. Cancer Res. 80, CT169 (2020). · DOI
  26. Khattak, A. et al. Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201/Keynote-942 trial. Cancer Res. 83, CT001 (2023). · DOI · Paper page
  27. Liu, M. et al. Improved T-cell immunity following neoadjuvant chemotherapy in ovarian cancer. Clin. Cancer Res. 28, 3356–3366 (2022). · DOI
  28. Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648 (2021). · DOI · Paper page
  29. Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022). · DOI · Paper page
  30. Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021). · DOI · Paper page
  31. Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019). · DOI · Paper page
  32. Pauken, K. E. et al. The PD-1 pathway regulates development and function of memory CD8+ T cells following respiratory viral infection. Cell Rep. 31, 107827 (2020). · DOI
  33. Azari, Z. et al. The role of immune cells in therapeutic angiogenesis: concepts in tissue engineering. Curr. Opin. Biomed. Eng. 28, 100470 (2023). · DOI
  34. Frantz, S., Vincent, K. A., Feron, O. & Kelly, R. A. Innate immunity and angiogenesis. Circ. Res. 96, 15–26 (2005). · DOI · Paper page
  35. Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020). · DOI · Paper page
  36. Frigola, X. et al. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol. Lett. 142, 78–82 (2012). · DOI
  37. Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018). · DOI · Paper page
  38. Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018). · DOI · Paper page
  39. Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202–1216 (2024). · DOI · Paper page
  40. Albiges, L., Flippot, R., Rioux-Leclercq, N. & Choueiri, T. K. Non-clear cell renal cell carcinomas: from shadow to light. J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.79.2531 (2018). · DOI
  41. Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359–1371 (2024). · DOI · Paper page
  42. Liu, N., Zhou, Y. & Lee, J. J. IPDfromKM: reconstruct individual patient data from published Kaplan–Meier survival curves. BMC Med. Res. Methodol. 21, 111 (2021). · DOI · Paper page
  43. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011). · DOI · Paper page
  44. Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39, 361–379 (2021). · DOI · Paper page
  45. Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531–534 (2018). · DOI
  46. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601–2602 (2011). · DOI · Paper page
  47. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013). · DOI · Paper page
  48. Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs. Bioinformatics 28, 1811–1817 (2012). · DOI · Paper page
  49. Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423–E2429 (2015). · DOI · Paper page
  50. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012). · DOI · Paper page
  51. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  52. Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199–209 (2020). · DOI · Paper page
  53. Jurtz, V. et al. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360–3368 (2017). · DOI · Paper page
  54. Lee, P. C. et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J. Clin. Invest. 132, e151666 (2022). · DOI
  55. Keskin, D. B. et al. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front. Immunol. 2, 75 (2011).
  56. Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience 7, giy083 (2018). · DOI · Paper page
  57. Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Research 9, 47 (2020). · DOI · Paper page
  58. Li, S. et al. RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat. Protoc. 14, 2571–2594 (2019). · DOI
  59. Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015). · DOI · Paper page
  60. Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315–326 (2017). · DOI · Paper page
  61. Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021). · DOI · Paper page

Cited by

See all 207

Metadata

Authors
Braun, D. A., Moranzoni, G., Chea, V., McGregor, B. A., Blass, E., Tu, C. R., Vanasse, A. P., Forman, C., Forman, J., Afeyan, A. B., Schindler, N. R., Liu, Y., Li, S., Southard, J., Chang, S. L., Hirsch, M. S., LeBoeuf, N. R., Olive, O., Mehndiratta, A., Greenslade, H., Shetty, K., Klaeger, S., Sarkizova, S., Pedersen, C. B., Mossanen, M., Carulli, I., Tarren, A., Duke-Cohan, J., Howard, A. A., Iorgulescu, J. B., Shim, B., Simon, J. M., Signoretti, S., Aster, J. C., Elagina, L., Carr, S. A., Leshchiner, I., Getz, G., Gabriel, S., Hacohen, N., Olsen, L. R., Oliveira, G., Neuberg, D. S., Livak, K. J., Shukla, S. A., Fritsch, E. F., Wu, C. J., Keskin, D. B., Ott, P. A., & Choueiri, T. K.
Venue
Nature
Published
2025-02-05
Volume
639
Issue
8054
Pages
474-482
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4407157630
Cited by
207
References
24
FWCI
61.41
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41586-024-08507-5
The paper
Braun, D. A., Moranzoni, G., Chea, V., McGregor, B. A., Blass, E., Tu, C. R., Vanasse, A. P., Forman, C., Forman, J., Afeyan, A. B., Schindler, N. R., Liu, Y., Li, S., Southard, J., Chang, S. L., Hirsch, M. S., LeBoeuf, N. R., Olive, O., Mehndiratta, A., . . . Choueiri, T. K. (2025). A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. https://doi.org/10.1038/s41586-024-08507-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.